Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens

Thomas M. Pisansky, Michael L. Blute, Vera Jean Suman, David G. Bostwick, John D. Earle, Horst Zincke

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: This study was conducted to identify pretherapy factors associated with seminal vesicle invasion (SVI) in patients with localized carcinoma of the prostate (CAP), and to develop a model that would allow estimation of the likelihood for SVI at the time of initial diagnosis. Methods and Materials: Between January 1988 and December 1993, 2959 patients underwent radical retropubic prostatectomy, with or without pelvic lymph node dissection, as initial therapy for clinical Stage T1a-3bN0-XM0 CaP. Preoperative patient and tumor-related characteristics were evaluated for an association with SVI in univariate and multivariate logistic regression analyses. A model was developed and probability plots were constructed to display the estimated likelihood for SVI in the patient with a new diagnosis of localized CaP. Results: Within clinical tumor stage, three groups (T1a- 2a, T2b-c, and T3a-b) were observed to have a distinctly different rate of SVI. Gleason primary grades were combined (1-2, 3, and 4-5) because of a similar observation. Univariate analysis identified clinical tumor stage (p < 0.0001), Gleason primary grade (p < 0.0001), and serum prostate-specific antigen level (p < 0.0001) as factors associated with the likelihood for SVI. Multivariate analysis confirmed the independent significance (p = 0.0001) of each of these factors. Patient age (p = 0.16) and history of prior transurethral resection of the prostate (p = 0.82) were not associated with this end point. Probability plots were constructed to display the likelihood of SVI as a function of pretherapy clinical tumor stage, Gleason primary grade, and serum prostate-specific antigen value. Conclusion: In the patient with a new diagnosis of localized CaP, clinical tumor stage as determined by digital rectal examination, diagnostic biopsy tumor (Gleason primary) grade, and pretherapy serum prostate-specific antigen value were significant factors for development of a model that estimated the likelihood of SVI. Estimates from this type of model may be of value in the pretherapy diagnostic evaluation of such patients, and may aid in the administration of radiation therapy.

Original languageEnglish (US)
Pages (from-to)585-591
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume36
Issue number3
DOIs
StatePublished - Oct 1 1996

Fingerprint

Seminal Vesicles
Prostatectomy
Prostatic Neoplasms
cancer
tumors
grade
antigens
serums
Prostate-Specific Antigen
Neoplasms
plots
Serum
dissection
lymphatic system
Digital Rectal Examination
logistics
Transurethral Resection of Prostate
Lymph Node Excision
regression analysis
radiation therapy

Keywords

  • Grade
  • Neoplasm staging
  • Prostate cancer
  • Prostate-specific antigen/bl (blood)
  • Prostatectomy
  • Prostatic neoplasms/pa (pathology)
  • Seminal vesicles/pa (pathology)
  • Stage

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. / Pisansky, Thomas M.; Blute, Michael L.; Suman, Vera Jean; Bostwick, David G.; Earle, John D.; Zincke, Horst.

In: International Journal of Radiation Oncology Biology Physics, Vol. 36, No. 3, 01.10.1996, p. 585-591.

Research output: Contribution to journalArticle

Pisansky, Thomas M. ; Blute, Michael L. ; Suman, Vera Jean ; Bostwick, David G. ; Earle, John D. ; Zincke, Horst. / Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. In: International Journal of Radiation Oncology Biology Physics. 1996 ; Vol. 36, No. 3. pp. 585-591.
@article{d433205f6cf24eb2ae8884503db1d645,
title = "Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens",
abstract = "Purpose: This study was conducted to identify pretherapy factors associated with seminal vesicle invasion (SVI) in patients with localized carcinoma of the prostate (CAP), and to develop a model that would allow estimation of the likelihood for SVI at the time of initial diagnosis. Methods and Materials: Between January 1988 and December 1993, 2959 patients underwent radical retropubic prostatectomy, with or without pelvic lymph node dissection, as initial therapy for clinical Stage T1a-3bN0-XM0 CaP. Preoperative patient and tumor-related characteristics were evaluated for an association with SVI in univariate and multivariate logistic regression analyses. A model was developed and probability plots were constructed to display the estimated likelihood for SVI in the patient with a new diagnosis of localized CaP. Results: Within clinical tumor stage, three groups (T1a- 2a, T2b-c, and T3a-b) were observed to have a distinctly different rate of SVI. Gleason primary grades were combined (1-2, 3, and 4-5) because of a similar observation. Univariate analysis identified clinical tumor stage (p < 0.0001), Gleason primary grade (p < 0.0001), and serum prostate-specific antigen level (p < 0.0001) as factors associated with the likelihood for SVI. Multivariate analysis confirmed the independent significance (p = 0.0001) of each of these factors. Patient age (p = 0.16) and history of prior transurethral resection of the prostate (p = 0.82) were not associated with this end point. Probability plots were constructed to display the likelihood of SVI as a function of pretherapy clinical tumor stage, Gleason primary grade, and serum prostate-specific antigen value. Conclusion: In the patient with a new diagnosis of localized CaP, clinical tumor stage as determined by digital rectal examination, diagnostic biopsy tumor (Gleason primary) grade, and pretherapy serum prostate-specific antigen value were significant factors for development of a model that estimated the likelihood of SVI. Estimates from this type of model may be of value in the pretherapy diagnostic evaluation of such patients, and may aid in the administration of radiation therapy.",
keywords = "Grade, Neoplasm staging, Prostate cancer, Prostate-specific antigen/bl (blood), Prostatectomy, Prostatic neoplasms/pa (pathology), Seminal vesicles/pa (pathology), Stage",
author = "Pisansky, {Thomas M.} and Blute, {Michael L.} and Suman, {Vera Jean} and Bostwick, {David G.} and Earle, {John D.} and Horst Zincke",
year = "1996",
month = "10",
day = "1",
doi = "10.1016/S0360-3016(96)00359-8",
language = "English (US)",
volume = "36",
pages = "585--591",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens

AU - Pisansky, Thomas M.

AU - Blute, Michael L.

AU - Suman, Vera Jean

AU - Bostwick, David G.

AU - Earle, John D.

AU - Zincke, Horst

PY - 1996/10/1

Y1 - 1996/10/1

N2 - Purpose: This study was conducted to identify pretherapy factors associated with seminal vesicle invasion (SVI) in patients with localized carcinoma of the prostate (CAP), and to develop a model that would allow estimation of the likelihood for SVI at the time of initial diagnosis. Methods and Materials: Between January 1988 and December 1993, 2959 patients underwent radical retropubic prostatectomy, with or without pelvic lymph node dissection, as initial therapy for clinical Stage T1a-3bN0-XM0 CaP. Preoperative patient and tumor-related characteristics were evaluated for an association with SVI in univariate and multivariate logistic regression analyses. A model was developed and probability plots were constructed to display the estimated likelihood for SVI in the patient with a new diagnosis of localized CaP. Results: Within clinical tumor stage, three groups (T1a- 2a, T2b-c, and T3a-b) were observed to have a distinctly different rate of SVI. Gleason primary grades were combined (1-2, 3, and 4-5) because of a similar observation. Univariate analysis identified clinical tumor stage (p < 0.0001), Gleason primary grade (p < 0.0001), and serum prostate-specific antigen level (p < 0.0001) as factors associated with the likelihood for SVI. Multivariate analysis confirmed the independent significance (p = 0.0001) of each of these factors. Patient age (p = 0.16) and history of prior transurethral resection of the prostate (p = 0.82) were not associated with this end point. Probability plots were constructed to display the likelihood of SVI as a function of pretherapy clinical tumor stage, Gleason primary grade, and serum prostate-specific antigen value. Conclusion: In the patient with a new diagnosis of localized CaP, clinical tumor stage as determined by digital rectal examination, diagnostic biopsy tumor (Gleason primary) grade, and pretherapy serum prostate-specific antigen value were significant factors for development of a model that estimated the likelihood of SVI. Estimates from this type of model may be of value in the pretherapy diagnostic evaluation of such patients, and may aid in the administration of radiation therapy.

AB - Purpose: This study was conducted to identify pretherapy factors associated with seminal vesicle invasion (SVI) in patients with localized carcinoma of the prostate (CAP), and to develop a model that would allow estimation of the likelihood for SVI at the time of initial diagnosis. Methods and Materials: Between January 1988 and December 1993, 2959 patients underwent radical retropubic prostatectomy, with or without pelvic lymph node dissection, as initial therapy for clinical Stage T1a-3bN0-XM0 CaP. Preoperative patient and tumor-related characteristics were evaluated for an association with SVI in univariate and multivariate logistic regression analyses. A model was developed and probability plots were constructed to display the estimated likelihood for SVI in the patient with a new diagnosis of localized CaP. Results: Within clinical tumor stage, three groups (T1a- 2a, T2b-c, and T3a-b) were observed to have a distinctly different rate of SVI. Gleason primary grades were combined (1-2, 3, and 4-5) because of a similar observation. Univariate analysis identified clinical tumor stage (p < 0.0001), Gleason primary grade (p < 0.0001), and serum prostate-specific antigen level (p < 0.0001) as factors associated with the likelihood for SVI. Multivariate analysis confirmed the independent significance (p = 0.0001) of each of these factors. Patient age (p = 0.16) and history of prior transurethral resection of the prostate (p = 0.82) were not associated with this end point. Probability plots were constructed to display the likelihood of SVI as a function of pretherapy clinical tumor stage, Gleason primary grade, and serum prostate-specific antigen value. Conclusion: In the patient with a new diagnosis of localized CaP, clinical tumor stage as determined by digital rectal examination, diagnostic biopsy tumor (Gleason primary) grade, and pretherapy serum prostate-specific antigen value were significant factors for development of a model that estimated the likelihood of SVI. Estimates from this type of model may be of value in the pretherapy diagnostic evaluation of such patients, and may aid in the administration of radiation therapy.

KW - Grade

KW - Neoplasm staging

KW - Prostate cancer

KW - Prostate-specific antigen/bl (blood)

KW - Prostatectomy

KW - Prostatic neoplasms/pa (pathology)

KW - Seminal vesicles/pa (pathology)

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=0030272187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030272187&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(96)00359-8

DO - 10.1016/S0360-3016(96)00359-8

M3 - Article

C2 - 8948342

AN - SCOPUS:0030272187

VL - 36

SP - 585

EP - 591

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -